QView Medical

QView Medical is a pioneer in AI-driven diagnostics for breast cancer, with a team possessing a 20-year legacy in securing FDA Premarket Approvals (PMAs) for CAD systems. The company's flagship product, QVCAD, is the first FDA-approved CAD system for 3D Automated Breast Ultrasound (ABUS) screening, specifically targeting the significant challenge of detecting cancer in women with dense breast tissue where mammography is less effective. The company is currently commercial, with its technology live in clinical production at sites like Eve Wellness in San Francisco. QView operates at the intersection of AI, medical imaging, and regulatory expertise, aiming to establish a new standard of care in supplemental breast cancer screening.

AI-powered Computer-Aided Detection (CAD) software platform for 3D Automated Breast Ultrasound (ABUS). The platform analyzes entire breast volumes to identify and characterize potential lesions, providing radiologists with an efficient, synthesized overview of screening exams.

QView competes in the AI radiology software market, specifically for breast imaging. Direct competitors include other AI startups developing algorithms for breast ultrasound (e.g., Koios Medical, ScreenPoint Medical). Indirect but potent competitors are the large imaging equipment manufacturers (GE, Hologic, Siemens) who can develop and bundle AI software directly with their ABUS hardware. QView's differentiation is its specific FDA PMA for ABUS CAD and its team's deep regulatory heritage.